drugset / Trial / NCT04485156

Summary

The purpose of this study is to investigate the effectiveness and safety of the regimen including high dose rifampicin for individualized duration (3 months after Culture Conversion) for the treatment of drug-sensitive pulmonary tuberculosis.

Timeline

Start
2020-09
Primary completion
2025-08
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ethambutol Small molecule 15 mg/kg
Comparator Ethambutol Small molecule 20 mg/kg
Subject Rifampin Small molecule 10 mg/kg
Subject Rifampin Small molecule 30 mg/kg
Background Isoniazid Small molecule 300 mg
Background Pyrazinamide Small molecule 20 mg/kg
Background Pyrazinamide Small molecule 30 mg/kg
Background Pyrazinamide Small molecule 1000 mg
Background Pyrazinamide Small molecule 1500 mg
Background Pyrazinamide Small molecule 2000 mg